Literature DB >> 29081472

Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study.

Akinori Sawamura1, Takahiro Okumura1, Akihiro Hirakawa2, Masaaki Ito3, Yukio Ozaki4, Nobuyuki Ohte5, Tetsuya Amano6, Toyoaki Murohara1.   

Abstract

BACKGROUND: Cardiac recovery and prevention of end-organ damage are the cornerstones of establishing successful bridge to recovery (BTR) in patients with fulminant myocarditis (FM) supported with percutaneous venoarterial extracorporeal membrane oxygenation (VA-ECMO). However, the timing and method of successful BTR prediction still remain unclear. We aimed to develop a prediction model for successful BTR in patients with FM supported with percutaneous VA-ECMO.Methods and 
Results: This was a retrospective multicenter chart review enrolling 99 patients (52±16 years; female, 42%) with FM treated with percutaneous VA-ECMO. The S-group comprised patients who experienced percutaneous VA-ECMO decannulation and subsequent discharge (n=46), and the F-group comprised patients who either died in hospital or required conversion to other forms of mechanical circulatory support (n=53). At VA-ECMO initiation (0-h), the S-group had significantly higher left ventricular ejection fraction (LVEF) and lower aspartate aminotransferase (AST) concentration than the F-group. At 48 h, the LVEF, increase in the LVEF, and reduction of AST from 0-h were identified as independent predictors in the S-group. Finally, we developed an S-group prediction model comprising these 3 variables (area under the curve, 0.844; 95% confidence interval, 0.745-0.944).
CONCLUSIONS: We developed a model for use 48 h after VA-ECMO initiation to predict successful BTR in patients with FM.

Entities:  

Keywords:  Bridge to recovery; Extracorporeal membrane oxygenation; Fulminant myocarditis; Mechanical circulatory support; Prediction model

Mesh:

Substances:

Year:  2017        PMID: 29081472     DOI: 10.1253/circj.CJ-17-0549

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Myocardial strain features by 2D-STE during the course of fulminant myocarditis: Correlation with characteristics by CMR and clinical implications.

Authors:  Houjuan Zuo; Haojie Li; Rui Li; Fei Ma; Jiangang Jiang; Chenze Li; Liming Xia; Hong Wang; Dao Wen Wang
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

2.  Differences in Prognosis and Cardiac Function According to Required Percutaneous Mechanical Circulatory Support and Histological Findings in Patients With Fulminant Myocarditis: Insights From the CHANGE PUMP 2 Study.

Authors:  Toru Kondo; Takahiro Okumura; Naoki Shibata; Takahiro Imaizumi; Kaoru Dohi; Hideo Izawa; Nobuyuki Ohte; Tetsuya Amano; Toyoaki Murohara
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

Review 3.  Overview of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support for the Management of Cardiogenic Shock.

Authors:  Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos
Journal:  Front Cardiovasc Med       Date:  2021-07-07

4.  Extensive Loss of Myocardium due to Lymphocytic Fulminant Myocarditis: An Autopsy Case Report of a Patient with Persistent Cardiac Arrest for 25 Days.

Authors:  Kei Morikawa; Seiji Takashio; Ryota Sato; Eiichiro Yamamoto; Koichi Kaikita; Kenichi Tsujita; Yoshihiro Komohara
Journal:  Intern Med       Date:  2020-08-12       Impact factor: 1.271

5.  Efficacy of central extracorporeal life support for patients with fulminant myocarditis and cardiogenic shock.

Authors:  Naoki Tadokoro; Satsuki Fukushima; Kimito Minami; Takura Taguchi; Tetsuya Saito; Naonori Kawamoto; Takashi Kakuta; Osamu Seguchi; Takuya Watanabe; Seiko Nakajima Doi; Kensuke Kuroda; Keisuke Suzuki; Masanobu Yanase; Yasuhide Asaumi; Hideyuki Shimizu; Norihide Fukushima; Tomoyuki Fujita
Journal:  Eur J Cardiothorac Surg       Date:  2021-11-02       Impact factor: 4.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.